Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Indivior to Announce First Quarter 2018 Results on May 2nd and Host Conference Call

Indivior PLC
Posted on: 11 Apr 18
Indivior to Announce First Quarter 2018 Results on May 2nd and Host Conference Call

PR Newswire

SLOUGH, England and RICHMOND, Va., April 11, 2018

SLOUGH, England and RICHMOND, Va., April 11, 2018 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced that it will release its first quarter 2018 results on May 2nd at 12:00 p.m.London time (7:00 a.m. U.S. Eastern). The results will be available via the London Stock Exchange's Regulatory News Service (RNS) and on the "Investors" section of the company's website at www.indivior.com.

Key members of Indivior's leadership team led by Shaun Thaxter, Chief Executive Officer, will host a conference call to discuss the results and address questions from qualified analysts and investors at 1:00 p.m.London time (8:00 a.m. U.S. Eastern) on May 2nd.

Access the Live Webcast for the Results Call on May 2nd
The webcast event will be available on the "Investors" section of the company's website at www.indivior.com. The webcast link is https://edge.media-server.com/m6/p/dq3mbvwq. Participants also may access the results presentation telephonically: US participants 1-323-794-2149; international participants 44(0)330-336-9411. Please reference confirmation number 1140953. A replay of the presentation will be available at www.indivior.com.

About Indivior
Indivior is a global specialty pharmaceutical company with a 20-year legacy of leadership in patient advocacy and health policy while providing education on evidence-based treatment models that have revolutionized modern addiction treatment. The name is the fusion of the words individual and endeavour, and the tagline "Focus on you" makes the Company's commitment clear. Indivior is dedicated to transforming addiction from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of opioid dependence treatments, Indivior has a strong pipeline of product candidates designed to both expand on its heritage in this category and address other chronic conditions and co-occurring disorders of addiction, including alcohol use disorder and schizophrenia. Headquartered in the United States in Richmond, VA, Indivior employs more than 900 individuals globally and its portfolio of products is available in over 40 countries worldwide. Visit www.indivior.com to learn more.

Contact:
Jason Thompson
Vice President, Investor Relations
Tel: 804-423-8916 or jason.thompson@indivior.com

View original content with multimedia:http://www.prnewswire.com/news-releases/indivior-to-announce-first-quarter-2018-results-on-may-2nd-and-host-conference-call-300627579.html

SOURCE Indivior PLC

PR Newswire
www.prnewswire.com

Last updated on: 11/04/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.